Suvish Drugs And Marbles Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 16-11-2024
- Paid Up Capital ₹ 1.50 M
as on 16-11-2024
- Company Age 35 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 6.93 M
as on 16-11-2024
- Revenue 120.08%
(FY 2023)
- Profit 7514.88%
(FY 2023)
- Ebitda 72588.79%
(FY 2023)
- Net Worth 5.37%
(FY 2023)
- Total Assets 5.39%
(FY 2023)
About Suvish Drugs And Marbles
The Company is engaged in the Manufacturing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M.
The company has closed loans amounting to ₹6.93 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Lalit Sharma and Suresh Sharma serve as directors at the Company.
- CIN/LLPIN
U55100RJ1989PTC005207
- Company No.
005207
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Nov 1989
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Udaipur, Rajasthan, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Suvish Drugs And Marbles?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lalit Sharma  | Director | 07-Nov-2007 | Current |
| Suresh Sharma | Director | 07-Nov-2007 | Current |
Financial Performance of Suvish Drugs And Marbles.
Suvish Drugs And Marbles Pvt. Ltd., for the financial year ended 2023, experienced significant growth in revenue, with a 120.08% increase. The company also saw a substantial improvement in profitability, with a 7514.88% increase in profit. The company's net worth moved up by a moderate rise of 5.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Suvish Drugs And Marbles?
In 2023, Suvish Drugs And Marbles had a promoter holding of 91.33% and a public holding of 8.67%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Hotel Riddhi Inn Private LimitedActive 11 years 4 monthsLalit Sharma and Suresh Sharma are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Syndicate Bank Creation Date: 16 Jan 1998 | ₹1.35 M | Satisfied |
Syndicate Bank Creation Date: 08 Mar 1995 | ₹0.83 M | Satisfied |
Syndicate Bank Creation Date: 26 Apr 1991 | ₹0.98 M | Satisfied |
How Many Employees Work at Suvish Drugs And Marbles?
Unlock and access historical data on people associated with Suvish Drugs And Marbles, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Suvish Drugs And Marbles, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Suvish Drugs And Marbles's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
